BioTracesVision: Work with leaders in the industry to develop and commercialize novel instruments and assays that enable the identification, quantitation and sequencing of sub-attomole quantities of proteins, nucleic acids and other bio-molecules
Leading to: The discovery of new proteins and advancements in the understanding of biological pathways, disease mechanisms, and cell function
Thereby: Creating value in the fields of drug development, clinical and research diagnostics, therapy design and monitoring, and life science research, including agricultural biotechnology

Hot from BioTraces:
Instrumentation:
August 1999 The SR-MPD/384 developed.
November 1999 The new electronic read-out (center-of-gravity) method for SR-MPD developed.
February 2000 The MPD-Imager/900 developed
April 2000 The development of SR-MPD/MT1516 initiated

Biomedical assays:
November 1999 The mqPCR for concurrent quantitation of three DNA targets developed.
December 1999 The new reagents for MPD enabled immunoassays developed.
January 2000 The new more sensitive immunoassay for HIV-1 developed.
February 2000 The quantitation of HIV-1 gag down to a few copies demonstrated
high throughput microtiter format.

Instruments & Description

Company location:
BioTraces, Inc.,  13455 Sunrise Valley Dr., Suite 200 Herndon, VA 20171

For additional information about BioTraces please contact:
Dr. A.K.Drukier, (703)-793 1550 ext 108 or e-mail: akd@biotraces.com
HOME ABOUT BIOTRACES MPD TECHNOLOGY MPD INSTRUMENTATION BIOMEDICAL APPLICATION of MPD TARGET MARKET SERVICES